Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 5Genitourinary 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Glioma 1

Interventions

Filgrastim 12Carboplatin 10Paclitaxel 9Peripheral Blood Stem Cell Transplantation 7Cyclophosphamide 7Ifosfamide 6Temozolomide 5Cisplatin 5pembrolizumab 4Nivolumab 4Gemcitabine 4Etoposide 4Docetaxel 4fludarabine 3Thiotepa 3Specimen Handling 3Psychiatric Rehabilitation 3Melphalan 3Magnetic Resonance Spectroscopy 3Immunologic Techniques 3Fluorodeoxyglucose F18 3Flow Cytometry 3Bevacizumab 3Amifostine 3ulixertinib 2trametinib 2sargramostim 2sapanisertib 2pegfilgrastim 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Platinum Compounds × CNS × Clear all
NCT04851834 2022-12-20

NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma

Xennials Therapeutics Australia Pty Ltd

Phase 1/2 Terminated
12 enrolled
CNSGenitourinaryGynecologic

Urinary Bladder Neoplasms, Glioma, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡